Xbrane Biopharma AB (XBRANE) Stock Statistics & Valuation Metrics

Xbrane Biopharma AB has a market cap or net worth of kr133.91M. The enterprise value is kr47.75M.

Xbrane Biopharma AB has 20,605,349 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xbrane Biopharma AB’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is -5.02%.

The current PE Ratio of Xbrane Biopharma AB is 0.5. Xbrane Biopharma AB’s PEG ratio is -1.22.

In the last 12 months, Xbrane Biopharma AB had revenue of 152.35M and earned 127.24M in profits. Earnings per share was 0.08.

In the last 12 months, operating cash flow was -250.69M and capital expenditures -72.95M, giving a free cash flow of -323.64M billion.

Xbrane Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Xbrane Biopharma AB upcoming earnings date is May 5, 2026, TBA (Confirmed).

Xbrane Biopharma AB as a current ratio of 7.12, with Debt / Equity ratio of 10.40%

In the past 12 months, Xbrane Biopharma AB has paid 2.23M in taxes.

Xbrane Biopharma AB EV to EBITDA ratio is -939.14, with an EV/FCF ratio of -61.81.

Xbrane Biopharma AB has kr86.59M in cash and marketable securities with kr58.31M in debt, giving a net cash position of kr28.28M billion.

Gross margin is 55.13%, with operating margin of -20.41%, and net profit margin of 83.52%.

The average price target for Xbrane Biopharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―